Venglustat (GZ402671)

DRUG4 trials

Sponsors

Genzyme, a Sanofi Company, Sanofi

Conditions

Fabry DiseaseGaucher Disease Type 1Gaucher Disease Type 3Hepatic Function Abnormal

Phase 1

A Study in Adults to Investigate the Impact of Mild, Moderate, and Severe Hepatic Impairment on Pharmacokinetics of Venglustat Compared to Participants With Normal Hepatic Function

CompletedNCT05718258

SanofiHepatic Function Abnormal

Start: 2023-01-18End: 2024-01-29Updated: 2025-09-15

Phase 2

Venglustat in Combination With Cerezyme in Adult Patients With Gaucher Disease Type 3 With Venglustat Monotherapy Extension

Active, not recruitingNCT02843035

Genzyme, a Sanofi CompanyGaucher Disease Type 1, Gaucher Disease Type 3

Start: 2017-01-04End: 2026-10-30Updated: 2025-03-26

Phase 3

A Study to Evaluate the Effect of Venglustat Tablets on Neuropathic and Abdominal Pain in Male and Female Participants ≥16 Years of Age With Fabry Disease

Active, not recruitingNCT05206773

SanofiFabry Disease

Start: 2022-03-11End: 2027-01-04Updated: 2026-02-04

A Study to Evaluate the Effect of Venglustat Tablets on Left Ventricular Mass Index in Male and Female Adult Participants With Fabry Disease

Active, not recruitingNCT05280548

SanofiFabry Disease

Start: 2022-05-03End: 2027-12-06Updated: 2026-03-10

Related Papers

Qualitative Study of the Patient Experience with Venglustat for Gaucher Disease Type 3 in a Phase 2 Open-Label, Multicenter, Multinational Study (LEAP).

2024-05-277 citations

Venglustat combined with imiglucerase for neurological disease in adults with Gaucher disease type 3: the LEAP trial

Brain2022-10-1438 citations

Safety, Pharmacokinetics, and Pharmacodynamics of Oral Venglustat in Patients with Parkinson’s Disease and a GBA Mutation: Results from Part 1 of the Randomized, Double-Blinded, Placebo-Controlled MOVES-PD Trial

Journal of Parkinson s Disease2021-12-1059 citations